Ropinirole in Gilles de la Tourette syndrome

被引：38

作者：

Anca, MH

Giladi, N

Korczyn, AD ^{[1
]}

机构：

[1] Tel Aviv Univ, Sackler Fac Med, Dept Neurol, Sieratzki Chair Neurol, IL-69978 Ramat Aviv, Israel

[2] Tel Aviv Univ, Tel Aviv Med Ctr, Dept Neurol, IL-69978 Ramat Aviv, Israel

来源：

NEUROLOGY | 2004年 / 62卷 / 09期

关键词：

D O I：

10.1212/01.WNL.0000123111.00324.BF

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The effects of treatment with ropinirole (0.25 to 0.5 mg bid) were examined using an open-label design for 8 weeks in 15 subjects with Gilles de la Tourette syndrome (GdlT). All patients completed the study, and most showed an improvement in their tics during treatment. Low-dose ropinirole may improve the motor features in GdlT, but further controlled studies are necessary.

引用

页码：1626 / 1627

页数：2

共 11 条

[1]

Black KJ, 2000, MOVEMENT DISORD, V15, P1194, DOI 10.1002/1531-8257(200011)15:6<1194::AID-MDS1019>3.0.CO

[2]

2-H

[3] Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells [J].